Literature DB >> 24968865

ADRM1 gene amplification is a candidate driver for metastatic gastric cancers.

Seok Hoon Jang1, Jun Won Park, Hyo Rim Kim, Je Kyung Seong, Hark Kyun Kim.   

Abstract

We searched for candidate target genes in metastatic gastric cancer, using comparative genomic hybridization (CGH) and mRNA expression array analysis of endoscopic biopsy samples collected from 32 patients. Recurrent amplicons included 17q21.2 (36,569,293-37,307,055), 8q24.13-q24.21 (126,357,475-130,159,285), and 20q13.33 (60,211,249-61,382,787). In this paper, we focused on the 1.1-Mb genomic region containing 24 genes in chromosome 20q13.33 (from 60,211,249 to 61,382,787), the third most frequent amplicon that was amplified in three of 32 patients (9.4 %), with log2 tumor/reference ratios ranging from 0.6 to 1.5. Of three genes in the 20q13.33 amplicon, ADRM1 was chosen for functional analyses. ADRM1 knockdown suppressed the proliferation of two human gastric cancer cells, SNU-601 and SNU-216. Overexpression of Adrm1 promoted cell proliferation of conditionally-immortalized, mouse ImSt gastric epithelial cells, with increased S1 phase fraction and decreased expression of p21(Cip1). These results collectively indicate that ADRM1 promoted gastric epithelial cell proliferation by cell cycle progression. Therefore, ADRM1 is a candidate target gene in the chromosome 20q13.33 amplicon that may possibly be linked to development of gastric cancer.

Entities:  

Mesh:

Year:  2014        PMID: 24968865     DOI: 10.1007/s10585-014-9663-4

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  21 in total

1.  A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13/ADRM1 as a therapy for cancer.

Authors:  Ravi K Anchoori; Balasubramanyam Karanam; Shiwen Peng; Joshua W Wang; Rosie Jiang; Toshihiko Tanno; Robert Z Orlowski; William Matsui; Ming Zhao; Michelle A Rudek; Chien-fu Hung; Xiang Chen; Kylie J Walters; Richard B S Roden
Journal:  Cancer Cell       Date:  2013-12-09       Impact factor: 31.743

2.  Proteasome recruitment and activation of the Uch37 deubiquitinating enzyme by Adrm1.

Authors:  Tingting Yao; Ling Song; Wei Xu; George N DeMartino; Laurence Florens; Selene K Swanson; Michael P Washburn; Ronald C Conaway; Joan Weliky Conaway; Robert E Cohen
Journal:  Nat Cell Biol       Date:  2006-08-13       Impact factor: 28.824

3.  hRpn13/ADRM1/GP110 is a novel proteasome subunit that binds the deubiquitinating enzyme, UCH37.

Authors:  Xiao-Bo Qiu; Song-Ying Ouyang; Chao-Jun Li; Shiying Miao; Linfang Wang; Alfred L Goldberg
Journal:  EMBO J       Date:  2006-11-30       Impact factor: 11.598

4.  UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme.

Authors:  Yoshiaki Okamoto; Toshinori Ozaki; Kou Miyazaki; Mineyoshi Aoyama; Masaru Miyazaki; Akira Nakagawara
Journal:  Cancer Res       Date:  2003-07-15       Impact factor: 12.701

5.  Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target.

Authors:  Marlena S Fejzo; Judy Dering; Chuck Ginther; Lee Anderson; Lilian Ramos; Christine Walsh; Beth Karlan; Dennis J Slamon
Journal:  Genes Chromosomes Cancer       Date:  2008-10       Impact factor: 5.006

6.  Epidermal growth factor receptor activation protects gastric epithelial cells from Helicobacter pylori-induced apoptosis.

Authors:  Fang Yan; Hanwei Cao; Rupesh Chaturvedi; Uma Krishna; Stuart S Hobbs; Peter J Dempsey; Richard M Peek; Timothy L Cover; M Kay Washington; Keith T Wilson; D Brent Polk
Journal:  Gastroenterology       Date:  2009-01-01       Impact factor: 22.682

7.  Identification of genes with a correlation between copy number and expression in gastric cancer.

Authors:  Lei Cheng; Ping Wang; Sheng Yang; Yanqing Yang; Qing Zhang; Wen Zhang; Huasheng Xiao; Hengjun Gao; Qinghua Zhang
Journal:  BMC Med Genomics       Date:  2012-05-04       Impact factor: 3.063

8.  A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients.

Authors:  Hark Kyun Kim; Il Ju Choi; Chan Gyoo Kim; Hee Sung Kim; Akira Oshima; Aleksandra Michalowski; Jeffrey E Green
Journal:  PLoS One       Date:  2011-02-18       Impact factor: 3.240

9.  Amplification of the 20q chromosomal arm occurs early in tumorigenic transformation and may initiate cancer.

Authors:  Yuval Tabach; Ira Kogan-Sakin; Yosef Buganim; Hilla Solomon; Naomi Goldfinger; Randi Hovland; Xi-Song Ke; Anne M Oyan; Karl-H Kalland; Varda Rotter; Eytan Domany
Journal:  PLoS One       Date:  2011-01-31       Impact factor: 3.240

10.  Integration of DNA copy number alterations and transcriptional expression analysis in human gastric cancer.

Authors:  Biao Fan; Somkid Dachrut; Ho Coral; Siu Tsan Yuen; Kent Man Chu; Simon Law; Lianhai Zhang; Jiafu Ji; Suet Yi Leung; Xin Chen
Journal:  PLoS One       Date:  2012-04-23       Impact factor: 3.240

View more
  16 in total

1.  Expression of DDX27 contributes to colony-forming ability of gastric cancer cells and correlates with poor prognosis in gastric cancer.

Authors:  Yoshiyuki Tsukamoto; Shoichi Fumoto; Tsuyoshi Noguchi; Kazuyoshi Yanagihara; Yuka Hirashita; Chisato Nakada; Naoki Hijiya; Tomohisa Uchida; Keiko Matsuura; Ryoji Hamanaka; Kazunari Murakami; Masao Seto; Masafumi Inomata; Masatsugu Moriyama
Journal:  Am J Cancer Res       Date:  2015-09-15       Impact factor: 6.166

2.  Structures of Rpn1 T1:Rad23 and hRpn13:hPLIC2 Reveal Distinct Binding Mechanisms between Substrate Receptors and Shuttle Factors of the Proteasome.

Authors:  Xiang Chen; Leah Randles; Ke Shi; Sergey G Tarasov; Hideki Aihara; Kylie J Walters
Journal:  Structure       Date:  2016-07-07       Impact factor: 5.006

3.  Phosphorylation of Tyr-950 in the proteasome scaffolding protein RPN2 modulates its interaction with the ubiquitin receptor RPN13.

Authors:  Casey W Hemmis; Stephanie C Heard; Christopher P Hill
Journal:  J Biol Chem       Date:  2019-05-07       Impact factor: 5.157

4.  Structure and energetics of pairwise interactions between proteasome subunits RPN2, RPN13, and ubiquitin clarify a substrate recruitment mechanism.

Authors:  Ryan T VanderLinden; Casey W Hemmis; Tingting Yao; Howard Robinson; Christopher P Hill
Journal:  J Biol Chem       Date:  2017-04-25       Impact factor: 5.157

5.  Impact of Losing hRpn13 Pru or UCHL5 on Proteasome Clearance of Ubiquitinated Proteins and RA190 Cytotoxicity.

Authors:  Vasty Osei-Amponsa; Vinidhra Sridharan; Mayank Tandon; Christine N Evans; Kimberly Klarmann; Kwong Tai Cheng; Justin Lack; Raj Chari; Kylie J Walters
Journal:  Mol Cell Biol       Date:  2020-08-28       Impact factor: 4.272

6.  The Proteasome Ubiquitin Receptor hRpn13 and Its Interacting Deubiquitinating Enzyme Uch37 Are Required for Proper Cell Cycle Progression.

Authors:  Leah Randles; Ravi K Anchoori; Richard B S Roden; Kylie J Walters
Journal:  J Biol Chem       Date:  2016-02-23       Impact factor: 5.157

7.  Somatic amplifications and deletions in genome of papillary thyroid carcinomas.

Authors:  Nadia Passon; Elisa Bregant; Marialuisa Sponziello; Maria Dima; Francesca Rosignolo; Cosimo Durante; Marilena Celano; Diego Russo; Sebastiano Filetti; Giuseppe Damante
Journal:  Endocrine       Date:  2015-04-12       Impact factor: 3.633

8.  Mechanistic Studies of the Multiple Myeloma and Melanoma Cell-Selective Toxicity of the Rpn13-Binding Peptoid KDT-11.

Authors:  Paige Dickson; Scott Simanski; John Maina Ngundu; Thomas Kodadek
Journal:  Cell Chem Biol       Date:  2020-08-27       Impact factor: 8.116

9.  Upregulation of LINC00659 expression predicts a poor prognosis and promotes migration and invasion of gastric cancer cells.

Authors:  Pihai Gong; Ying Xu; Min Liu; Xiaohui Shen; Yuhang Mao; Yiping Li; Kun Zhang; Shenling Yu; Hong Fan
Journal:  Oncol Lett       Date:  2021-05-24       Impact factor: 2.967

10.  Network Biomarkers of Bladder Cancer Based on a Genome-Wide Genetic and Epigenetic Network Derived from Next-Generation Sequencing Data.

Authors:  Cheng-Wei Li; Bor-Sen Chen
Journal:  Dis Markers       Date:  2016-02-29       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.